TO: The Honorable Shane E. Pendergrass, Chair
    Members, House Health and Government Operations Committee
    The Honorable Erek L. Barron

FROM: Pamela Metz Kasemeyer
       J. Steven Wise
       Danna L. Kauffman
       Richard A. Tabuteau

DATE: January 30, 2018


The Maryland State Medical Society, the Maryland Chapter of the American College of Emergency Physicians, the Maryland Chapter of the American Congress of Obstetricians and Gynecologists, the Mid-Atlantic Association of Community Health Centers, and the Maryland Chapter of the American Academy of Pediatrics wish to register their opposition to House Bill 88.

House Bill 88 proposes to amend and expand Maryland’s Prescription Drug Monitoring Program (PDMP) to require, instead of authorizing, PDMP to review prescription monitoring data for indications of possible misuse or abuse of a monitored prescription drug or a possible violation of law or breach of professional standards by a prescriber or dispenser. If the PDMP determines there is a possible violation of law or breach of professional standards, the bill authorizes the PDMP to notify the appropriate law enforcement agency or health occupations board and requires the program to provide the agency or board with the data necessary for an investigation. While the PDMP must take specified factors into account regarding a possible violation of law or breach of professional standards, it nonetheless provides authority for the PDMP to directly refer cases to law enforcement or professional boards without review by the technical advisory committee.

While the members of these organizations applaud the sponsors for their dedication to addressing this very real public health crisis, they assert that the provisions of House Bill 88 are premature and will undermine not only the objectives of the PDMP but may also negatively impact the Maryland Department of Health’s (MDH) efforts to enhance the enforcement activities of the Office of Controlled Substances Administration (OCSA). House Bill 88 has the potential to generate unsupported investigations and disciplinary actions based on incomplete or inaccurate data. As or more important, it will negatively impact the current workplan of MDH and its contractor CRISP to continue its careful, quality focused, methodical build out of the PDMP capabilities.

At hearings before this Committee and in its September 18th letter to the Senate and House Committee leadership addressing the status of the implementation of providing education and notice of a possible violation of law or a possible breach of professional standards and whether the authority of the PDMP possible violations of law or possible breaches of professional standards should be expanded, MDH clearly stated that for the next 12 months, the Department intends to focus on fulfilling its three primary initiatives with respect to the PDMP:
(1) achieving 100% compliance with the July 1, 2017, PDMP mandatory registration requirement of Controlled Dangerous Substance (CDS) prescribers and pharmacists; (2) continuing outreach and education efforts on CDS prescriptions to lower the number of unnecessary or inappropriate prescriptions in Maryland; and (3) preparing for and achieving compliance with the July 1, 2018, PDMP use and dispensing mandate.

Further, MDH noted that OCSA has expanded its enforcement efforts to enable the Department to identify CDS non-compliance, provide data analysis, and to conduct case investigations that may result in action against a registrant’s CDS registration. These actions may include disciplinary actions, such as educational awareness warnings, corrective action plans, CDS restrictions, revocation of registration, and referral for action by the Department Office of the Inspector General, Medicaid Fraud Office, Office of the Attorney General, Drug Enforcement Administration, and other relevant entities.

House Bill 88 fails to recognize the technical and capacity limitations of the PDMP that are still being addressed as well as MDH’s continued efforts to enhance the operational coordination and effectiveness of OCSA and the PDMP to ensure that OCSA is able to carry out its statutory enforcement responsibilities. MDH must be permitted to continue its current workplan for program implementation before there is any consideration of requirements for mandatory data analysis or authority for direct referral to law enforcement or the professional boards.

The above-named organizations are strong advocates for an accessible and accurate PDMP that can serve as a valuable tool to inform clinical decisions. They wish to continue to actively partner with both the Administration and General Assembly in identifying meaningful and effective approaches to reducing the incidences of addiction and overdose deaths. House Bill 88 does not advance those objectives and may have a counter-productive impact on their attainment. An unfavorable report is respectively requested.

For more information call:
Pamela Metz Kasemeyer
J. Steven Wise
Danna L. Kauffman
Richard Tabuteau
(410) 244-7000